宫内造血细胞移植治疗重型α地中海贫血的1期临床试验
在6例重型α地中海贫血胎儿中开展1期临床试验,于孕23.1±1.1周经宫内移植母源CD34+细胞(1.33×10^8±2.67×10^7细胞/kg+1%T细胞),所有胎儿接受系列宫内输血并足月或近足月分娩。围产期结局与单纯宫内输血者大致相似,未发生胎儿不良事件,但供者细胞因竞争劣势未能持久植入,提示无骨髓预处理时IUHCT治疗ATM的局限性。
要点
- 宫内移植母源CD34+细胞在ATM胎儿中安全可行,围产期结局与单纯宫内输血相似。
- 所有受者检测到低水平母源微嵌合,但供者细胞因宿主造血干细胞扩增而处于竞争劣势。
- 多数子代神经发育评估良好、生活质量评分高,支持产前宫内输血的价值。
核心结论
- IUHCT治疗重型α地中海贫血方案安全可行,但无骨髓预处理时供者细胞植入受限。
研究设计与样本
- 1期临床试验纳入6例重型α地中海贫血胎儿,于孕23.1±1.1周移植母源CD34+细胞(1.33×10^8±2.67×10^7细胞/kg+1%T细胞)。
- 同期分析单纯接受宫内输血的ATM胎儿结局作为对照。
- 试验注册号NCT02986698。
主要发现
- 所有受者接受系列宫内输血并足月或近足月分娩,围产期结局与单纯宫内输血者大致相似。
- 所有受者检测到低水平母源微嵌合,2/6子代出现对母源抗原的T细胞低反应性,但仅1例持续。
- ATM妊娠脐血中宿主造血干/祖细胞较健康对照显著扩增,提示供者细胞处于竞争劣势。
- 神经发育评估大多令人放心,生活质量评分高。
- 2例母亲因收获细胞晚期培养阳性接受预防性抗生素,未发生胎儿不良事件。
临床怎么用
- 产前宫内输血可改善ATM胎儿围产期及神经发育结局。
- 无预处理条件下IUHCT暂不能作为ATM的根治手段,需进一步研究。
局限性
- 样本量小(6例移植胎儿),为1期试验。
- 未设随机对照,对照为同期单纯宫内输血者。
- 随访时间有限,T细胞低反应性仅1例持续。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In utero hematopoietic cell transplantation (IUHCT) has the potential to treat patients who have hemoglobinopathies by harnessing the unique period of fetal tolerance to maternal cells, thereby enabling semiallogeneic transplantation without conditioning or immunosuppression. We conducted a phase 1 clinical trial of IUHCT in fetuses with α-thalassemia major (ATM), a diagnosis that requires serial in utero transfusions (IUT) for survival. We also analyzed outcomes in fetuses with ATM treated with IUT alone in the same time period. Six fetuses underwent transplantation with maternal CD34+ cells (1.33 × 108 ± 2.67 × 107 cells per kg + 1% T cells) at 23.1 ± 1.1 weeks' gestation. All received serial IUT and were delivered at, or near, term. Perinatal outcomes were broadly similar to those undergoing IUT alone. Two mothers received prophylactic antibiotics because of late positive cultures of harvested cells (without fetal adverse events). Low-level maternal microchimerism was detected in all recipients; T-cell hyporeactivity to maternal antigens was detected in 2 of 6 offspring but persisted in only 1 child. Cord blood from ATM-affected pregnancies demonstrated marked expansion of host hematopoietic stem and progenitor cells compared with healthy controls, suggesting a competitive disadvantage for donor cells in this disease context. Neurodevelopmental assessments were largely reassuring, with high quality-of-life scores. Overall, this protocol was safe and feasible but demonstrates the limitations of IUHCT for ATM without concurrent bone marrow conditioning. The favorable perinatal and neurologic outcomes in most offspring underscore the benefits of prenatal transfusions and the unmet medical need for developing definitive therapies for ATM. This trial was registered at www.clinicaltrials.gov as NCT02986698.
引用
- MacKenzie TC, Lianoglou BR, Gonzalez Velez J, et al. In utero hematopoietic cell transplantation in fetuses with α-thalassemia major: a phase 1 clinical trial. Blood Adv. 2026. PMID: 41984996. doi:10.1182/bloodadvances.2026019655
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。